134615-37-5

Basic information

• Product Name: REVEROMYCIN A
• Synonyms: REVEROMYCIN A;ZESGNAJSBDILTB-OXVOKJAASA-N
• CAS NO: 134615-37-5
• Molecular Formula: C36H52O11
• Molecular Weight: 660.79
• Product Categories: Antineoplastic and Immunosuppressive AntibioticsReceptor Tyrosine Kinase Biology;Epidermal Growth Factor Receptor (EGFR)Antibiotics;Interferes with Protein Synthesis;Antibiotics;Antibiotics A to;Antibiotics by Application;Antibiotics N-SAntibiotics;AntifungalAntibiotics;Mechanism of Action;Receptor Tyrosine Kinase Inhibitors;Spectrum of Activity
• Mol File: 134615-37-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 849°Cat760mmHg
• Flash Point: 258.7°C
• Appearance: /solid
• Density: 1.21g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: −20°C
• Solubility: DMF: soluble
• PKA: 4.36±0.17(Predicted)
• CAS DataBase Reference: REVEROMYCIN A(CAS DataBase Reference)
• NIST Chemistry Reference: REVEROMYCIN A(134615-37-5)
• EPA Substance Registry System: REVEROMYCIN A(134615-37-5)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 134615-37-5(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 134615-37-5 differently. You can refer to the following data:
1. Reveromycin A, the dominant analogue of a complex of spiroketals isolated from a Streptomyces sp., is an inhibitor of the mitogenic activity of EGF. Reveromycin A is a G1 phase cell cycle inhibitor, selectively inhibiting isoleucyl-tRNA synthetase. Reveromycin A displays antiproliferative behaviour against human cell lines KB and K562, as well as potent antifungal activity. More recently it has been shown to induce apoptosis in osteoclasts thus inhibiting bone resorption.
2. Reveromycin A is a spiroketal antibiotic inhibitor of EGF mitogenic activity. Inhibits the signal transduction of the epidermal growth factor. May be used

InChI:InChI=1/C36H52O11/c1-6-7-19-35(47-34(44)17-16-32(40)41)21-22-36(46-30(35)14-10-25(3)23-33(42)43)20-18-27(5)29(45-36)13-9-24(2)8-12-28(37)26(4)11-15-31(38)39/h8-12,14-15,23,26-30,37H,6-7,13,16-22H2,1-5H3,(H,38,39)(H,40,41)(H,42,43)/b12-8+,14-10+,15-11+,24-9+,25-23+/t26-,27-,28-,29+,30-,35+,36-/m0/s1

Upstream product

• 297741-51-6 succinic acid allyl ester 2-(4-allyloxycarbonyl-3-methyl-buta-1,3-dienyl)-3-butyl-8-[6-(tert-butyl-dimethyl-silanyloxy)-3,7-dimethyl-8-triethylsilanyloxy-octa-2,4-dienyl]-9-methyl-1,7-dioxa-spiro[5.5]undec-3-yl ester 
• 297741-53-8 succinic acid allyl ester 8-[9-allyloxycarbonyl-6-(tert-butyl-dimethyl-silanyloxy)-3,7-dimethyl-nona-2,4,8-trienyl]-2-(4-allyloxycarbonyl-3-methyl-buta-1,3-dienyl)-3-butyl-9-methyl-1,7-dioxa-spiro[5.5]undec-3-yl ester 
• 297741-52-7 Succinic acid allyl ester (2S,3R,6S,8R,9S)-2-((1E,3E)-4-allyloxycarbonyl-3-methyl-buta-1,3-dienyl)-3-butyl-8-[(2E,4E)-(6S,7R)-6-(tert-butyl-dimethyl-silanyloxy)-3,7-dimethyl-8-oxo-octa-2,4-dienyl]-9-methyl-1,7-dioxa-spiro[5.5]undec-3-yl ester 
• 297741-50-5 Succinic acid allyl ester (2S,3R,6S,8R,9S)-2-((1E,3E)-4-allyloxycarbonyl-3-methyl-buta-1,3-dienyl)-8-[(E)-4-(benzothiazole-2-sulfonyl)-3-methyl-but-2-enyl]-3-butyl-9-methyl-1,7-dioxa-spiro[5.5]undec-3-yl ester 
• 297741-54-9 Succinic acid allyl ester (2S,3R,6S,8R,9S)-2-((1E,3E)-4-allyloxycarbonyl-3-methyl-buta-1,3-dienyl)-8-[(E)-4-(benzothiazol-2-ylsulfanyl)-3-methyl-but-2-enyl]-3-butyl-9-methyl-1,7-dioxa-spiro[5.5]undec-3-yl ester 
• 297741-44-7 Succinic acid allyl ester (2S,3R,6R,8R,9S)-3-butyl-2-(tert-butyldiphenylsilanyloxymethyl)-8-[2-(4-methoxybenzyloxy)ethyl]-9-methyl-1,7-dioxaspiro[5.5]undec-3-yl ester 
• 297741-49-2 Succinic acid allyl ester (2S,3R,6S,8R,9S)-2-((1E,3E)-4-allyloxycarbonyl-3-methyl-buta-1,3-dienyl)-3-butyl-8-((E)-4-hydroxy-3-methyl-but-2-enyl)-9-methyl-1,7-dioxa-spiro[5.5]undec-3-yl ester 
• 1053612-90-0 tert-Butyl-{(2S,3R,6R,8R,9S)-3-butyl-8-[2-(4-methoxy-benzyloxy)-ethyl]-9-methyl-3-methylsulfanylmethoxy-1,7-dioxa-spiro[5.5]undec-2-ylmethoxy}-diphenyl-silane 
• 297741-48-1 Succinic acid allyl ester (2S,3R,6S,8R,9S)-2-((1E,3E)-4-allyloxycarbonyl-3-methyl-buta-1,3-dienyl)-3-butyl-9-methyl-8-((E)-3-methyl-4-oxo-but-2-enyl)-1,7-dioxa-spiro[5.5]undec-3-yl ester 
• 297741-46-9 (2S,3R,6R,8R,9S)-3-Butyl-2-(tert-butyl-diphenyl-silanyloxymethyl)-8-[2-(4-methoxy-benzyloxy)-ethyl]-9-methyl-1,7-dioxa-spiro[5.5]undecan-3-ol 
• 297741-45-8 Succinic acid allyl ester (2S,3R,6R,8R,9S)-2-((1E,3E)-4-allyloxycarbonyl-3-methyl-buta-1,3-dienyl)-3-butyl-8-(2-hydroxy-ethyl)-9-methyl-1,7-dioxa-spiro[5.5]undec-3-yl ester 
• 297741-43-6 Succinic acid allyl ester (2S,3R,6S,8R,9S)-2-((1E,3E)-4-allyloxycarbonyl-3-methyl-buta-1,3-dienyl)-3-butyl-8-(2-hydroxy-ethyl)-9-methyl-1,7-dioxa-spiro[5.5]undec-3-yl ester 
• 1045798-76-2 Succinic acid allyl ester (2S,3R,6S,8R,9S)-2-((1E,3E)-4-allyloxycarbonyl-3-methyl-buta-1,3-dienyl)-3-butyl-9-methyl-8-(2-oxo-ethyl)-1,7-dioxa-spiro[5.5]undec-3-yl ester 
• 250379-08-9 Triethyl-{(1R,2S)-1-[2-(4-methoxy-benzyloxy)-ethyl]-2-methyl-but-3-ynyloxy}-silane 

Related news

Stabilization of tooth movement by administration of REVEROMYCIN A (cas 134615-37-5) to osteoprotegerin-deficient knockout mice07/30/2019

IntroductionIn this study, mechanical stress in the form of tooth movement was applied to osteoprotegerin-deficient knockout mice, which served as an animal model for juvenile Paget’s disease. To compare and evaluate bone turnover and response of the surrounding bony tissue, we administered rev...detailed

Relevant articles and documents

Total synthesis of (-)-reveromycin A via a hetero-Diels-Alder approach

The asymmetric total synthesis of (-)-reveromycin A is described which utilizes a Lewis acid catalyzed inverse electron demand hetero-Diels-Alder reaction followed by hydroboration/oxidation to afford the labile [6,6]-spiroketal core in a highly stereosel

Total synthesis of reveromycin A

matrix presented The stereoselective total synthesis of reveromycin A (1), a potent inhibitor of eukaryotic cell growth, has been accomplished on the basis of the stereocontrolled construction of the 6,6-spiroketal system, efficient succinylation of the t